Fenofibrate improves renal function by amelioration of NOX-4, IL-18, and p53 expression in an experimental model of diabetic nephropathy

Journal of Cellular Biochemistry

Volumn 119, Issue 9, 2018, Pages 7458-7469

  Yaribeygi, Habib ^a,b   Mohammadi, Mohammad T ^a,b   Rezaee, Ramin ^c   Sahebkar, Amirhossein ^c,d  

^a BAQIYATALLAH UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c MASHHAD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d MASHHAD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

diabetic nephropathy; fenofibrate; IL 18; NOX 4; p53; PPAR agonist

Indexed keywords

CREATININE; FENOFIBRATE; FREE RADICAL; GLUCOSE; GLUCOSE TRANSPORTER 1; GLUTATHIONE; INTERLEUKIN 18; MALONALDEHYDE; MESSENGER RNA; NITRATE; PROTEIN P53; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 4; UREA; URIC ACID; ANTILIPEMIC AGENT; STREPTOZOCIN;

ALBUMINURIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; APOPTOSIS; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; CREATININE URINE LEVEL; ENZYME ACTIVITY; EXPERIMENTAL DIABETIC NEPHROPATHY; GLOMERULOSCLEROSIS; GLUCOSE BLOOD LEVEL; HISTOPATHOLOGY; INFLAMMATION; KIDNEY FAILURE; KIDNEY FUNCTION; LIPID PEROXIDATION; MALE; MRNA EXPRESSION LEVEL; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; STREPTOZOTOCIN-INDUCED DIABETES MELLITUS; UREA NITROGEN BLOOD LEVEL; URIC ACID BLOOD LEVEL; URINALYSIS; WISTAR RAT; ANIMAL; COMPLICATION; DIABETIC NEPHROPATHY; DISEASE MODEL; DRUG EFFECT; EXPERIMENTAL DIABETES MELLITUS; GENE EXPRESSION REGULATION; GENETICS; KIDNEY; PATHOPHYSIOLOGY;

ANIMALS; APOPTOSIS; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC NEPHROPATHIES; DISEASE MODELS, ANIMAL; FENOFIBRATE; GENE EXPRESSION REGULATION; HYPOLIPIDEMIC AGENTS; INFLAMMATION; INTERLEUKIN-18; KIDNEY; MALE; NADPH OXIDASE 4; OXIDATIVE STRESS; RATS; RATS, WISTAR; STREPTOZOCIN; TUMOR SUPPRESSOR PROTEIN P53;

EID: 85051712011     PISSN: 07302312     EISSN: 10974644     Source Type: Journal    
DOI: 10.1002/jcb.27055     Document Type: Article

References (54)

1. Gross JL, De Azevedo MJ, Silveiro SP, Canani LH, Caramori ML, Zelmanovitz T. Diabetic nephropathy: diagnosis, prevention, and treatment. Diabetes Care. 2005; 28:164–176.
2. Arora MK, Singh UK. Molecular mechanisms in the pathogenesis of diabetic nephropathy: an update. Vascul Pharmacol. 2013; 58:259–271.
3. Vincent AM, Russell JW, Low P, Feldman EL. Oxidative stress in the pathogenesis of diabetic neuropathy. Endocr Rev. 2004; 25:612–628.
4. Jha JC, Gray SP, Barit D, et al. Genetic targeting or pharmacologic inhibition of NADPH oxidase nox4 provides renoprotection in long-term diabetic nephropathy. J Am Soc Nephrol. 2014; 25:1237–1254.
5. Gorin Y, Cavaglieri RC, Khazim K, et al. Targeting NADPH oxidase with a novel dual Nox1/Nox4 inhibitor attenuates renal pathology in type 1 diabetes. Am J Physiol Renal Physiol. 2015; 308:F1276–F1287.
6. Sedeek M, Callera G, Montezano A, et al. Critical role of Nox4-based NADPH oxidase in glucose-induced oxidative stress in the kidney: implications in type 2 diabetic nephropathy. Am J Physiol Renal Physiol. 2010; 299:F1348–F1358.
7. Mahadev K, Motoshima H, Wu X, et al. The NAD (P) H oxidase homolog Nox4 modulates insulin-stimulated generation of H2O2 and plays an integral role in insulin signal transduction. Mol Cell Biol. 2004; 24:1844–1854.
8. Thallas-Bonke V, Jha JC, Gray SP, et al. Nox-4 deletion reduces oxidative stress and injury by PKC-α-associated mechanisms in diabetic nephropathy. Physiol Rep. 2014; 2:e12192.
9. Duran-Salgado MB, Rubio-Guerra AF. Diabetic nephropathy and inflammation. World J Diabetes. 2014; 5:393.
10. Fujita T, Ogihara N, Kamura Y, et al. Interleukin-18 contributes more closely to the progression of diabetic nephropathy than other diabetic complications. Acta Diabetol. 2012; 49:111–117.
11. Nakamura A, Shikata K, Hiramatsu M, et al. Serum interleukin-18 levels are associated with nephropathy and atherosclerosis in Japanese patients with type 2 diabetes. Diabetes Care. 2005; 28:2890–2895.
12. Lim AK, Tesch GH. Inflammation in diabetic nephropathy. Mediators Inflamm. 2012; 2012:Article ID 146154.
13. Isermann B, Vinnikov IA, Madhusudhan T, et al. Activated protein C protects against diabetic nephropathy by inhibiting endothelial and podocyte apoptosis. Nat Med. 2007; 13:1349–1358.
14. Tikoo K, Singh K, Kabra D, Sharma V, Gaikwad A. Change in histone H3 phosphorylation, MAP kinase p38, SIR 2 and p53 expression by resveratrol in preventing streptozotocin induced type I diabetic nephropathy. Free Radicl Res. 2008; 42:397–404.
15. Liu D, Xu Y. P53, oxidative stress, and aging. Antioxid Redox Signal. 2011; 15:1669–1678.
16. Schetter AJ, Heegaard NH, Harris CC. Inflammation and cancer: interweaving microRNA, free radical, cytokine and p53 pathways. Carcinogenesis. 2009; 31:37–49.
17. Rakhshandehroo M, Knoch B, Müller M, Kersten S. Peroxisome proliferator-activated receptor alpha target genes. PPAR Res. 2010; 2010:Article ID 612089.
18. Hou X, Shen YH, Li C, et al. PPARα agonist fenofibrate protects the kidney from hypertensive injury in spontaneously hypertensive rats via inhibition of oxidative stress and MAPK activity. Biochem Biophys Res Commun. 2010; 394:653–659.
19. Winterbourn CC, Hawkins RE, Brian M, Carrell R. The estimation of red cell superoxide dismutase activity. Transl Res. 1975; 85:337–341.
20. Aebi H. [13] Catalase in vitro. Methods Enzymol. 1984; 105:121–126.
21. Tietze F. Enzymic method for quantitative determination of nanogram amounts of total and oxidized glutathione: applications to mammalian blood and other tissues. Anal Biochem. 1969; 27:502–522.
22. Satoh M, Fujimoto S, Haruna Y, et al. NAD (P) H oxidase and uncoupled nitric oxide synthase are major sources of glomerular superoxide in rats with experimental diabetic nephropathy. Am J Physiol Renal Physiol. 2005; 288:F1144–F1152.
23. Granger DL, Taintor RR, Boockvar KS, Hibbs JB. Measurement of nitrate and nitrite in biological samples using nitrate reductase and Griess reaction. Methods Enzymol. 1996; 268:142–151.
24. Derosa G, Sahebkar A, Maffioli P. The role of various peroxisome proliferator-activated receptors and their ligands in clinical practice. J Cell Physiol. 2018; 233:153–161.
25. Sahebkar A, Chew GT, Watts GF. Recent advances in pharmacotherapy for hypertriglyceridemia. Prog Lipid Res. 2014; 56:47–66.
26. Sahebkar A, Watts GF. Challenges in the treatment of hypertriglyceridemia: glass half empty or half full? Expert Rev Clin Pharmacol. 2015; 8:363–366.
27. Sahebkar A, Hernández-Aguilera A, Abelló D, Sancho E, Camps J, Joven J. Systematic review and meta-analysis deciphering the impact of fibrates on paraoxonase-1 status. Metabolism. 2016; 65:609–622.
28. Yaribeygi H, Mohammadi MT, Sahebkar A. PPAR-α agonist improves hyperglycemia-induced oxidative stress in pancreatic cells by potentiating antioxidant defense system. Drug Res. 2018. [Epub ahead of print]. https://doi.org/10.1055/s-0043-121143
29. Simental-Mendía LE, Simental-Mendía M, Sánchez-García A, et al. Effect of fibrates on glycemic parameters: a systematic review and meta-analysis of randomized placebo-controlled trials. Pharmacol Res. 2018. [Epub ahead of print]. https://doi.org/10.1016/j.phrs.2017.12.030
30. Sahebkar A, Serban MC, Mikhailidis DP, et al. Head-to-head comparison of statins versus fibrates in reducing plasma fibrinogen concentrations: a systematic review and meta-analysis. Pharmacol Res. 2016; 103:236–252.
31. Sahebkar A, Simental-Mendía LE, Watts GF, Golledge J. Impact of fibrate therapy on plasma plasminogen activator inhibitor-1: a systematic review and meta-analysis of randomized controlled trials. Atherosclerosis. 2015; 240:284–296.
32. Sahebkar A, Simental-Mendía LE, Watts GF, Serban MC, Banach M. Comparison of the effects of fibrates versus statins on plasma lipoprotein(a) concentrations: a systematic review and meta-analysis of head-to-head randomized controlled trials. BMC Med. 2017; 15:22.
33. Derosa G, Maffioli P, Sahebkar A. Plasma uric acid concentrations are reduced by fenofibrate: a systematic review and meta-analysis of randomized placebo-controlled trials. Pharmacol Res. 2015; 102:63–70.
34. Sahebkar A, Watts GF. Fibrate therapy and circulating adiponectin concentrations: asystematic review and meta-analysis of randomized placebo-controlled trials. Atherosclerosis. 2013; 230:110–120.
35. Sahebkar A, Giua R, Pedone C, Ray KK, Vallejo-Vaz AJ, Costanzo L. Fibrate therapy and flow-mediated dilation: a systematic review and meta-analysis of randomized placebo-controlled trials. Pharmacol Res. 2016; 111:163–179.
36. Forbes JM, Coughlan MT, Cooper ME. Oxidative stress as a major culprit in kidney disease in diabetes. Diabetes. 2008; 57:1446–1454.
37. Cheng R, Ding L, He X, Takahashi Y, Ma J-X. Interaction of PPARalpha with the Wnt pathway, a mechanism for the therapeutic effect of fenofibrate on diabetic nephropathy. Diabetes. 2016; 12:db160426.
38. Elmarakby AA, Sullivan JC. Relationship between oxidative stress and inflammatory cytokines in diabetic nephropathy. Cardiovasc Ther. 2012; 30:49–59.
39. Rodríguez-Iturbe B, Quiroz Y, Shahkarami A, Li Z, Vaziri ND. Mycophenolate mofetil ameliorates nephropathy in the obese Zucker rat. Kidney Int. 2005; 68:1041–1047.
40. Wittmann S, Daniel C, Stief A, Vogelbacher R, Amann K, Hugo C. Long-term treatment of sirolimus but not cyclosporine ameliorates diabetic nephropathy in the rat. Transplantation. 2009; 87:1290–1299.
41. Dinarello C. Interleukin-18, a proinflammatory cytokine. Eur Cytokine Netw. 2000; 11:483–486.
42. Moriwaki Y, Yamamoto T, Shibutani Y, et al. Elevated levels of interleukin-18 and tumor necrosis factor-α in serum of patients with type 2 diabetes mellitus: relationship with diabetic nephropathy. Metabolism. 2003; 52:605–608.
43. Ide A, Kawasaki E, Abiru N, et al. Association between IL-18 gene promoter polymorphisms and CTLA-4 gene 49A/G polymorphism in Japanese patients with type 1 diabetes. J Autoimmun. 2004; 22:73–78.
44. Lee JW, Bajwa PJ, Carson MJ, et al. Fenofibrate represses interleukin-17 and interferon-γ expression and improves colitis in interleukin-10-deficient mice. Gastroenterology. 2007; 133:108–123.
45. Liu Q, Li J, Liu Z, Ma J-X. Salutary effect of fenofibrate on diabetic retinopathy via inhibiting oxidative stress-mediated wnt pathway activation. Invest Ophthalmol Vis Sci. 2014; 55:1027–1027.
46. Zanetti M, Stocca A, Dapas B, et al. Inhibitory effects of fenofibrate on apoptosis and cell proliferation in human endothelial cells in high glucose. J Mol Med. 2008; 86:185–195.
47. Buttke TM, Sandstrom PA. Oxidative stress as a mediator of apoptosis. Immunol Today. 1994; 15:7–10.
48. Holmin S, Mathiesen T. Intracerebral administration of interleukin-1β and induction of inflammation, apoptosis, and vasogenic edema. J Neurosurg. 2000; 92:108–120.
49. Lieberthal W, Levine JS. Mechanisms of apoptosis and its potential role in renal tubular epithelial cell injury. Am J Physiol Renal Physiol. 1996; 271:F477–F488.
50. Lieberthal W, Koh JS, Levine JS. Necrosis and apoptosis in acute renal failure. Semin Nephrol. 1998; 18:505–518.
51. Tomizawa A, Hattori Y, Inoue T, Hattori S, Kasai K. Fenofibrate suppresses microvascular inflammation and apoptosis through adenosine monophosphate-activated protein kinase activation. Metabolism. 2011; 60:513–522.
52. De Silva DS, Wilson RM, Hutchinson C, et al. Fenofibrate inhibits aldosterone-induced apoptosis in adult rat ventricular myocytes via stress-activated kinase-dependent mechanisms. Am J Physiol Heart Circ Physiol. 2009; 296:H1983–H1993.
53. Sahebkar A, Chew GT, Watts GF. New peroxisome proliferator-activated receptor agonists: potential treatments for atherogenic dyslipidemia and non-alcoholic fatty liver disease. Expert Opin Pharmacother. 2014; 15:493–503.
54. Sahebkar A, Watts GF. Role of selective peroxisome proliferator-activated receptor modulators in managing cardiometabolic disease: tale of a roller-coaster. Diabetes Obes Metab. 2014; 16:780–792.